Cargando…
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study
BACKGROUND: Interstitial pneumonia (IP) is a poor prognostic comorbidity in patients with non-small cell lung cancer (NSCLC) and is also a risk factor for pneumonitis. The TORG1936/AMBITIOUS trial, the first known phase II study of atezolizumab in patients with NSCLC with comorbid IP, was terminated...
Autores principales: | Ikeda, Satoshi, Kato, Terufumi, Kenmotsu, Hirotsugu, Ogura, Takashi, Sato, Yuki, Hino, Aoi, Harada, Toshiyuki, Kubota, Kaoru, Tokito, Takaaki, Okamoto, Isamu, Furuya, Naoki, Yokoyama, Toshihide, Hosokawa, Shinobu, Iwasawa, Tae, Kasajima, Rika, Miyagi, Yohei, Misumi, Toshihiro, Okamoto, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438913/ https://www.ncbi.nlm.nih.gov/pubmed/35759340 http://dx.doi.org/10.1093/oncolo/oyac118 |
Ejemplares similares
-
A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020) -
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020) -
Rationale and protocol design for the TORG1835/NEXT-SHIP study: a
phase II study of carboplatin, etoposide and nintedanib for unresectable
limited/extensive disease small cell lung cancer with idiopathic pulmonary
fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2020) -
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
por: Gentzler, Ryan D, et al.
Publicado: (2023) -
An ambitious exploration
por: Malka, V
Publicado: (2014)